The Trump administration’s Centers for Medicare & Medicaid Services (CMS) has signaled that it will be revamping the process of negotiating prices for certain Medicare Part D drugs with input ...

Rigorous answers about the program’s effects on drug innovation are still a ways off. However, some information about ...

According to CMS data, Medicare Part D spending ... of Medicare negotiations yielded discounts on drugs ranging from 40 percent to 80 percent, including 76 percent off the list price for NovoLog.

In 2022, the U.S. Congress passed the Inflation Reduction Act, which gave Medicare the authority to negotiate certain prescription drug prices ... D. In August 2023, the Centers for Medicare and ...

CMS said it will announce maximum fair ... Human Services on the selection of 15 additional drugs under Medicare Part D for price negotiations. We are increasingly concerned about the impact ...

The proposal should be withdrawn. It is untethered to the Inflation Reduction Act and science and undercuts the incentive to ...

In the shadow of President Trump's efforts to lower drug prices, the Medicare drug price negotiation process that began in ...

or about 14% of Medicare Part D’s prescription drug costs, according to CMS. The negotiated prices for the drugs will take effect in 2027. The second round of negotiations builds on the success ...

Giving small-molecule drugs the same 13-year exemption from price negotiation as biologics would cost the federal government billions of dollars, argue three Harvard researchers ...